Home/Filings/4/0000899243-23-019274

4//SEC Filing

CRANDELL KEITH 4

Accession 0000899243-23-019274

CIK 0001885522other

View on SEC.gov Company Profile

Filed

Sep 19, 8:00 PM ET

Accepted

Sep 20, 6:16 AM ET

Size

41.1 KB

Accession

0000899243-23-019274

Insider Transaction Report

Form 4

Period: 2023-09-19

Neumora Therapeutics, Inc.NMRA

ARCH Venture Partners X, LLC

10% Owner

Transactions

Conversion
Common Stock
2023-09-19+684,167→ 684,167 total(indirect: By ARCH Venture Fund VII, L.P.)
Conversion
Common Stock
2023-09-19+1,144,973→ 1,144,973 total(indirect: By ARCH Venture Fund VIII Overage, L.P.)
Conversion
Common Stock
2023-09-19+6,576,400→ 11,886,758 total(indirect: By ARCH Venture Fund X Overage, L.P.)
Purchase
Common Stock
2023-09-19$17.00/sh+1,500,000$25,500,000→ 3,624,143 total(indirect: By ARCH Venture Fund XII, L.P.)
Conversion
Series A-1 Preferred Stock
2023-09-19−684,167→ 0 total(indirect: By ARCH Venture Fund VII, L.P.)
→ Common Stock (684,167 underlying)
Conversion
Series B Preferred Stock
2023-09-19−2,124,143→ 0 total(indirect: By ARCH Venture Fund XII, L.P.)
→ Common Stock (2,124,143 underlying)
Conversion
Common Stock
2023-09-19+6,895,021→ 12,205,379 total(indirect: By ARCH Venture Fund X, L.P.)
Conversion
Common Stock
2023-09-19+2,124,143→ 2,124,143 total(indirect: By ARCH Venture Fund XII, L.P.)
Conversion
Series A-1 Preferred Stock
2023-09-19−1,144,973→ 0 total(indirect: By ARCH Venture Fund VIII Overage, L.P.)
→ Common Stock (1,144,973 underlying)
Conversion
Series A-2 Preferred Stock
2023-09-19−6,576,400→ 0 total(indirect: By ARCH Venture Fund X Overage, L.P.)
→ Common Stock (6,576,400 underlying)
Conversion
Series A-2 Preferred Stock
2023-09-19−6,895,021→ 0 total(indirect: By ARCH Venture Fund X, L.P.)
→ Common Stock (6,895,021 underlying)

ARCH Venture Partners XII, LLC

10% Owner

Transactions

Conversion
Common Stock
2023-09-19+6,576,400→ 11,886,758 total(indirect: By ARCH Venture Fund X Overage, L.P.)
Conversion
Series A-2 Preferred Stock
2023-09-19−6,576,400→ 0 total(indirect: By ARCH Venture Fund X Overage, L.P.)
→ Common Stock (6,576,400 underlying)
Conversion
Common Stock
2023-09-19+684,167→ 684,167 total(indirect: By ARCH Venture Fund VII, L.P.)
Conversion
Common Stock
2023-09-19+6,895,021→ 12,205,379 total(indirect: By ARCH Venture Fund X, L.P.)
Conversion
Common Stock
2023-09-19+1,144,973→ 1,144,973 total(indirect: By ARCH Venture Fund VIII Overage, L.P.)
Conversion
Common Stock
2023-09-19+2,124,143→ 2,124,143 total(indirect: By ARCH Venture Fund XII, L.P.)
Purchase
Common Stock
2023-09-19$17.00/sh+1,500,000$25,500,000→ 3,624,143 total(indirect: By ARCH Venture Fund XII, L.P.)
Conversion
Series A-1 Preferred Stock
2023-09-19−1,144,973→ 0 total(indirect: By ARCH Venture Fund VIII Overage, L.P.)
→ Common Stock (1,144,973 underlying)
Conversion
Series A-1 Preferred Stock
2023-09-19−684,167→ 0 total(indirect: By ARCH Venture Fund VII, L.P.)
→ Common Stock (684,167 underlying)
Conversion
Series A-2 Preferred Stock
2023-09-19−6,895,021→ 0 total(indirect: By ARCH Venture Fund X, L.P.)
→ Common Stock (6,895,021 underlying)
Conversion
Series B Preferred Stock
2023-09-19−2,124,143→ 0 total(indirect: By ARCH Venture Fund XII, L.P.)
→ Common Stock (2,124,143 underlying)

GILLIS STEVEN

10% Owner

Transactions

Conversion
Common Stock
2023-09-19+684,167→ 684,167 total(indirect: By ARCH Venture Fund VII, L.P.)
Conversion
Common Stock
2023-09-19+6,576,400→ 11,886,758 total(indirect: By ARCH Venture Fund X Overage, L.P.)
Conversion
Common Stock
2023-09-19+6,895,021→ 12,205,379 total(indirect: By ARCH Venture Fund X, L.P.)
Conversion
Series A-2 Preferred Stock
2023-09-19−6,895,021→ 0 total(indirect: By ARCH Venture Fund X, L.P.)
→ Common Stock (6,895,021 underlying)
Conversion
Series A-1 Preferred Stock
2023-09-19−684,167→ 0 total(indirect: By ARCH Venture Fund VII, L.P.)
→ Common Stock (684,167 underlying)
Conversion
Common Stock
2023-09-19+1,144,973→ 1,144,973 total(indirect: By ARCH Venture Fund VIII Overage, L.P.)
Conversion
Common Stock
2023-09-19+2,124,143→ 2,124,143 total(indirect: By ARCH Venture Fund XII, L.P.)
Purchase
Common Stock
2023-09-19$17.00/sh+1,500,000$25,500,000→ 3,624,143 total(indirect: By ARCH Venture Fund XII, L.P.)
Conversion
Series A-2 Preferred Stock
2023-09-19−6,576,400→ 0 total(indirect: By ARCH Venture Fund X Overage, L.P.)
→ Common Stock (6,576,400 underlying)
Conversion
Series A-1 Preferred Stock
2023-09-19−1,144,973→ 0 total(indirect: By ARCH Venture Fund VIII Overage, L.P.)
→ Common Stock (1,144,973 underlying)
Conversion
Series B Preferred Stock
2023-09-19−2,124,143→ 0 total(indirect: By ARCH Venture Fund XII, L.P.)
→ Common Stock (2,124,143 underlying)

BYBEE CLINTON

10% Owner

Transactions

Conversion
Series B Preferred Stock
2023-09-19−2,124,143→ 0 total(indirect: By ARCH Venture Fund XII, L.P.)
→ Common Stock (2,124,143 underlying)
Conversion
Common Stock
2023-09-19+2,124,143→ 2,124,143 total(indirect: By ARCH Venture Fund XII, L.P.)
Purchase
Common Stock
2023-09-19$17.00/sh+1,500,000$25,500,000→ 3,624,143 total(indirect: By ARCH Venture Fund XII, L.P.)
Conversion
Common Stock
2023-09-19+1,144,973→ 1,144,973 total(indirect: By ARCH Venture Fund VIII Overage, L.P.)
Conversion
Common Stock
2023-09-19+6,895,021→ 12,205,379 total(indirect: By ARCH Venture Fund X, L.P.)
Conversion
Series A-2 Preferred Stock
2023-09-19−6,576,400→ 0 total(indirect: By ARCH Venture Fund X Overage, L.P.)
→ Common Stock (6,576,400 underlying)
Conversion
Common Stock
2023-09-19+684,167→ 684,167 total(indirect: By ARCH Venture Fund VII, L.P.)
Conversion
Common Stock
2023-09-19+6,576,400→ 11,886,758 total(indirect: By ARCH Venture Fund X Overage, L.P.)
Conversion
Series A-1 Preferred Stock
2023-09-19−684,167→ 0 total(indirect: By ARCH Venture Fund VII, L.P.)
→ Common Stock (684,167 underlying)
Conversion
Series A-1 Preferred Stock
2023-09-19−1,144,973→ 0 total(indirect: By ARCH Venture Fund VIII Overage, L.P.)
→ Common Stock (1,144,973 underlying)
Conversion
Series A-2 Preferred Stock
2023-09-19−6,895,021→ 0 total(indirect: By ARCH Venture Fund X, L.P.)
→ Common Stock (6,895,021 underlying)

ARCH Venture Partners XII, L.P.

10% Owner

Transactions

Conversion
Common Stock
2023-09-19+2,124,143→ 2,124,143 total(indirect: By ARCH Venture Fund XII, L.P.)
Conversion
Series A-1 Preferred Stock
2023-09-19−684,167→ 0 total(indirect: By ARCH Venture Fund VII, L.P.)
→ Common Stock (684,167 underlying)
Conversion
Series A-2 Preferred Stock
2023-09-19−6,895,021→ 0 total(indirect: By ARCH Venture Fund X, L.P.)
→ Common Stock (6,895,021 underlying)
Conversion
Series B Preferred Stock
2023-09-19−2,124,143→ 0 total(indirect: By ARCH Venture Fund XII, L.P.)
→ Common Stock (2,124,143 underlying)
Purchase
Common Stock
2023-09-19$17.00/sh+1,500,000$25,500,000→ 3,624,143 total(indirect: By ARCH Venture Fund XII, L.P.)
Conversion
Common Stock
2023-09-19+684,167→ 684,167 total(indirect: By ARCH Venture Fund VII, L.P.)
Conversion
Common Stock
2023-09-19+6,895,021→ 12,205,379 total(indirect: By ARCH Venture Fund X, L.P.)
Conversion
Common Stock
2023-09-19+1,144,973→ 1,144,973 total(indirect: By ARCH Venture Fund VIII Overage, L.P.)
Conversion
Common Stock
2023-09-19+6,576,400→ 11,886,758 total(indirect: By ARCH Venture Fund X Overage, L.P.)
Conversion
Series A-1 Preferred Stock
2023-09-19−1,144,973→ 0 total(indirect: By ARCH Venture Fund VIII Overage, L.P.)
→ Common Stock (1,144,973 underlying)
Conversion
Series A-2 Preferred Stock
2023-09-19−6,576,400→ 0 total(indirect: By ARCH Venture Fund X Overage, L.P.)
→ Common Stock (6,576,400 underlying)

ARCH Venture Fund XII, L.P.

10% Owner

Transactions

Purchase
Common Stock
2023-09-19$17.00/sh+1,500,000$25,500,000→ 3,624,143 total(indirect: By ARCH Venture Fund XII, L.P.)
Conversion
Common Stock
2023-09-19+684,167→ 684,167 total(indirect: By ARCH Venture Fund VII, L.P.)
Conversion
Common Stock
2023-09-19+6,895,021→ 12,205,379 total(indirect: By ARCH Venture Fund X, L.P.)
Conversion
Common Stock
2023-09-19+2,124,143→ 2,124,143 total(indirect: By ARCH Venture Fund XII, L.P.)
Conversion
Series A-1 Preferred Stock
2023-09-19−1,144,973→ 0 total(indirect: By ARCH Venture Fund VIII Overage, L.P.)
→ Common Stock (1,144,973 underlying)
Conversion
Common Stock
2023-09-19+1,144,973→ 1,144,973 total(indirect: By ARCH Venture Fund VIII Overage, L.P.)
Conversion
Common Stock
2023-09-19+6,576,400→ 11,886,758 total(indirect: By ARCH Venture Fund X Overage, L.P.)
Conversion
Series A-1 Preferred Stock
2023-09-19−684,167→ 0 total(indirect: By ARCH Venture Fund VII, L.P.)
→ Common Stock (684,167 underlying)
Conversion
Series B Preferred Stock
2023-09-19−2,124,143→ 0 total(indirect: By ARCH Venture Fund XII, L.P.)
→ Common Stock (2,124,143 underlying)
Conversion
Series A-2 Preferred Stock
2023-09-19−6,895,021→ 0 total(indirect: By ARCH Venture Fund X, L.P.)
→ Common Stock (6,895,021 underlying)
Conversion
Series A-2 Preferred Stock
2023-09-19−6,576,400→ 0 total(indirect: By ARCH Venture Fund X Overage, L.P.)
→ Common Stock (6,576,400 underlying)

NELSEN ROBERT

10% Owner

Transactions

Conversion
Series B Preferred Stock
2023-09-19−2,124,143→ 0 total(indirect: By ARCH Venture Fund XII, L.P.)
→ Common Stock (2,124,143 underlying)
Conversion
Common Stock
2023-09-19+6,576,400→ 11,886,758 total(indirect: By ARCH Venture Fund X Overage, L.P.)
Conversion
Series A-1 Preferred Stock
2023-09-19−684,167→ 0 total(indirect: By ARCH Venture Fund VII, L.P.)
→ Common Stock (684,167 underlying)
Conversion
Common Stock
2023-09-19+1,144,973→ 1,144,973 total(indirect: By ARCH Venture Fund VIII Overage, L.P.)
Conversion
Common Stock
2023-09-19+6,895,021→ 12,205,379 total(indirect: By ARCH Venture Fund X, L.P.)
Purchase
Common Stock
2023-09-19$17.00/sh+1,500,000$25,500,000→ 3,624,143 total(indirect: By ARCH Venture Fund XII, L.P.)
Conversion
Series A-2 Preferred Stock
2023-09-19−6,576,400→ 0 total(indirect: By ARCH Venture Fund X Overage, L.P.)
→ Common Stock (6,576,400 underlying)
Conversion
Common Stock
2023-09-19+684,167→ 684,167 total(indirect: By ARCH Venture Fund VII, L.P.)
Conversion
Common Stock
2023-09-19+2,124,143→ 2,124,143 total(indirect: By ARCH Venture Fund XII, L.P.)
Conversion
Series A-1 Preferred Stock
2023-09-19−1,144,973→ 0 total(indirect: By ARCH Venture Fund VIII Overage, L.P.)
→ Common Stock (1,144,973 underlying)
Conversion
Series A-2 Preferred Stock
2023-09-19−6,895,021→ 0 total(indirect: By ARCH Venture Fund X, L.P.)
→ Common Stock (6,895,021 underlying)

CRANDELL KEITH

10% Owner

Transactions

Conversion
Common Stock
2023-09-19+6,895,021→ 12,205,379 total(indirect: By ARCH Venture Fund X, L.P.)
Conversion
Series A-2 Preferred Stock
2023-09-19−6,576,400→ 0 total(indirect: By ARCH Venture Fund X Overage, L.P.)
→ Common Stock (6,576,400 underlying)
Conversion
Series A-1 Preferred Stock
2023-09-19−684,167→ 0 total(indirect: By ARCH Venture Fund VII, L.P.)
→ Common Stock (684,167 underlying)
Conversion
Series A-2 Preferred Stock
2023-09-19−6,895,021→ 0 total(indirect: By ARCH Venture Fund X, L.P.)
→ Common Stock (6,895,021 underlying)
Conversion
Series B Preferred Stock
2023-09-19−2,124,143→ 0 total(indirect: By ARCH Venture Fund XII, L.P.)
→ Common Stock (2,124,143 underlying)
Conversion
Common Stock
2023-09-19+684,167→ 684,167 total(indirect: By ARCH Venture Fund VII, L.P.)
Conversion
Common Stock
2023-09-19+1,144,973→ 1,144,973 total(indirect: By ARCH Venture Fund VIII Overage, L.P.)
Conversion
Common Stock
2023-09-19+6,576,400→ 11,886,758 total(indirect: By ARCH Venture Fund X Overage, L.P.)
Purchase
Common Stock
2023-09-19$17.00/sh+1,500,000$25,500,000→ 3,624,143 total(indirect: By ARCH Venture Fund XII, L.P.)
Conversion
Common Stock
2023-09-19+2,124,143→ 2,124,143 total(indirect: By ARCH Venture Fund XII, L.P.)
Conversion
Series A-1 Preferred Stock
2023-09-19−1,144,973→ 0 total(indirect: By ARCH Venture Fund VIII Overage, L.P.)
→ Common Stock (1,144,973 underlying)

Footnotes (7)

[F1]The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering.
[F2]Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
[F3]Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
[F4]Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.
[F5]Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
[F6]ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any.
[F7]Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Neumora Therapeutics, Inc.

CIK 0001885522

→

Entity typeother

Related Parties

filerCIK 0001219039

Filing Metadata

Form type: 4
Filed: Sep 19, 8:00 PM ET
Accepted: Sep 20, 6:16 AM ET
Size: 41.1 KB

View on SEC.gov